GlassScriptPhysician profile
Chirag Kapadia
NPI 1518175991
$13,169.11
in general payments reported to CMS, 2019-2025
39 companies · $5,069 in 2025
The $5,069 reported for 2025 was more than what 84% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $344 · 2021: $658 · 2022: $1,502 · 2023: $2,489 · 2024: $2,661 · 2025: $5,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,977 · Food and Beverage: $2,505 · Education: $378 · Long Term Medical Supply Or Device Loan: $250 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,976.51 |
| Food and Beverage | $2,504.83 |
| Education | $377.89 |
| Long Term Medical Supply Or Device Loan | $249.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $109.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,801.44 | 2019-2025 | Sogroya, Wegovy |
| Eton Pharmaceuticals, INC. | $2,561.60 | 2021-2025 | Alkindi, Increlex, Khindivi |
| Alexion Pharmaceuticals, INC. | $900.00 | 2023 | Strensiq |
| Abbott Laboratories | $558.89 | 2021-2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Incyte Corporation | $459.53 | 2023-2025 | Monjuvi, Jakafi, Monjuvi |
| Ipsen Biopharmaceuticals, INC | $391.21 | 2022-2025 | Onivyde |
| Pfizer INC. | $366.93 | 2019-2025 | |
| Abbvie INC. | $342.66 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $269.19 | 2023-2024 | |
| Ascendis Pharma Endocrinology INC | $248.34 | 2022-2024 | |
| Medtronic, INC. | $225.93 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Insulet Corporation | $198.84 | 2019-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $196.03 | 2020-2023 | Gvoke Hypopen |
| Arbor Pharmaceuticals, INC. | $194.15 | 2019-2022 | |
| Medtronic Minimed, INC. | $174.33 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $149.14 | 2020 | |
| Lilly USA, LLC | $128.42 | 2019-2023 | Baqsimi |
| Dexcom, INC. | $114.39 | 2019-2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Rhythm Pharmaceuticals, INC. | $107.79 | 2021-2024 | Imcivree, Imcivree |
| Astrazeneca Pharmaceuticals LP | $89.79 | 2024 | Calquence |
| Ultragenyx Pharmaceutical INC. | $83.15 | 2019-2021 | |
| Ascensia Diabetes Care US INC. | $64.33 | 2022-2024 | |
| Tolmar, INC. | $57.13 | 2023-2025 | Fensolvi |
| Genzyme Corporation | $55.02 | 2025 | |
| Neurocrine Biosciences, INC. | $50.37 | 2024-2025 | |
| Intuity Medical INC | $45.22 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Takeda Pharmaceuticals U.S.A., INC. | $44.58 | 2024-2025 | Livtencity, Alunbrig |
| Tolmar Pharmaceuticals, INC. | $42.75 | 2021-2022 | |
| Blueprint Medicines Corporation | $32.37 | 2024 | Ayvakit |
| Soleno Therapeutics, INC. | $31.28 | 2025 | Vykat Xr |
| Sumitomo Pharma America, INC. | $25.78 | 2024 | Orgovyx |
| Janssen Biotech, INC. | $25.25 | 2023 | Tecvayli, Darzalex |
| Geron Corporation | $22.68 | 2025 | Rytelo |
| Ferring Pharmaceuticals INC. | $20.07 | 2019 | |
| Tempus Ai, INC | $20.00 | 2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $19.77 | 2025 | |
| Zealand Pharma US, INC. | $18.61 | 2021 | |
| Morphosys, US INC. | $16.41 | 2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $15.74 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chirag Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.